LacriJet® is FCI latest and exclusive preloaded and self-retaining monocanalicular nasolacrimal intubation indicated for epiphora, congenital nasolacrimal duct obstruction and canalicular laceration.

Ritleng®+ is FCI’s latest autostable bicanalicular nasolacrimal intubation indicated for epiphora, canalicular pathologies, congenital lacrimal duct obstruction and dacryocystorhinostomy (DCR).

Since its inception in 1984, the ability to understand, anticipate and respond to the oculoplastic research has resulted in FCI’s strong portfolio of globally recognized products. FCI offers innovative solutions essential in the treatment of dry eye, lacrimal, eyelid, and orbit indications.